|
Sub-category:
Multidisciplinary Treatment
Category:
Esophagus and Stomach
Meeting:
2008 Gastrointestinal Cancers Symposium
Session Type and Session Title:
Oral Abstract Presentation A
General Poster Session B
Abstract No:
8
Author(s):
R. P. DeMatteo, K. Owzar, C. R. Antonescu, R. Maki, G. D. Demetri, M. McCarter, M. von Mehren, P. Pisters, M. F. Brennan, K. V. Ballman
Abstract:
Background: Prior to the availability of tyrosine kinase inhibitors, patients with high-risk primary GIST were reported to have a 2 year overall survival of approximately 50%. Since imatinib mesylate provides clinical benefit in over 80% of patients with metastatic GIST, we postulated that imatinib would be effective in the adjuvant setting following resection of localized, primary GIST. Methods: A single-arm, open-label, phase II multicenter study was performed. Patients underwent complete gross resection of a KIT-expressing primary GIST that was at high risk of recurrence (tumor size >10 cm, tumor rupture, or <5 peritoneal metastases). Histology was confirmed prospectively by a central pathologist. Imatinib was prescribed at a daily dose of 400 mg for 1 year. The primary endpoint was overall survival. Results: There were 107 evaluable patients enrolled between September 2001 and September 2003. Imatinib was initiated at a median of 59 (range 25-84) days after operation. The median age was 58 years (range 19-79). The median tumor size was 13 cm (range 3-42) and 50% of tumors originated from the stomach while 42% arose in the small intestine. Imatinib therapy was well tolerated as previously presented at the ASCO 2005 Annual Meeting. At a median follow-up of 4 years, the 1, 2, and 3 year overall survival rates were 99, 97, and 97%, respectively. The 1, 2, and 3 year recurrence-free survival rates were 94, 73, and 61%, respectively. Conclusions: Imatinib given at a daily oral dose of 400 mg for 1 year following the resection of a high-risk primary GIST prolongs recurrence-free survival and is associated with improved overall survival compared with historical controls.
Abstract Disclosures
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy
and are designated with a caret symbol (^) here and in the print version.
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by R. P. DeMatteo:
Presentations by R. P. DeMatteo:
Educational Book Manuscripts by R. P. DeMatteo:
|
